NIDDM: New aspects of management

Hospital Practice

Volumn 32, Issue 3, 1997, Pages 135-164

  Kitabchi, Abbas E ^a,b   Bryer Ash, Michael ^a,c  

^a UNIVERSITY OF TENNESSEE   (United States)

^b Dept of Medicine and Biochemistry ^*  (United States)

^c UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ACCUTRIM; ALPHA GLUCOSIDASE INHIBITOR; AMFEPRAMONE; ANOREXIGENIC AGENT; BANOBESE; BENZPHETAMINE; BIGUANIDE DERIVATIVE; CAFFEINE; CATECHOLAMINE DERIVATIVE; CHLORPROPAMIDE; DEXFENFLURAMINE; DIABINASE; EPHEDRINE; FENFLURAMINE; GLIBENCLAMIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; MAZINDOL; METFORMIN; OBENIX; OBY CAP; PHENDIMETRAZINE; PHENDIMETRAZINE TARTRATE; PHENTERMINE; PHENTERMINE RESIN; PHENYLPROPANOLAMINE; PRELU 2; PRESTAB; SULFONYLUREA DERIVATIVE; THIAZOLIDINE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE; UNCLASSIFIED DRUG; ZANTRYL;

DIET RESTRICTION; EXERCISE; HYPERGLYCEMIA; HYPERINSULINEMIA; INSULIN DEFICIENCY; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; REVIEW; RISK FACTOR;

EID: 0030995279     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.1080/21548331.1997.11443446     Document Type: Review

References (15)

1. American Diabetes Association: Clinical Practice Recommendations. Diabetes Care 20 (Suppl 1):S1, 1997
2. Bray, GA: Evaluation of drugs for treating obesity. Obes Res 3 (Suppl 4):425S, 1995
3. Chiasson J-L et al: The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121:928, 1994
4. DeFronzo RA et al: Efficacy of metformin in patients with NIDDM. N Engl J Med 333:541, 1995
5. Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977, 1993
6. Guy-Grand B: Clinical studies with dexfenfluramine: From past to future. Obes Res 3 (Suppl 4):491S, 1995
7. Kitabchi AE et al: Diabetes mellitus. In Primary Care in Gynecology, Ling FW et al (Eds). Williams & Wilkins, Baltimore, 1996, pp 279-298
8. King H, Rewers M: Global estimates for prevalence of diabetes and impaired glucose tolerance in adults. Diabetes Care 16:157, 1993
9. Konishi FJ: Food energy equivalents of various activities. J Am Diet Assoc 45:186, 1965
10. Lebovitz HE: Oral antidiabetic agents. In Joslin's Diabetes Mellitus, Kahn CR, Weir GC (Eds). Lea & Febiger, Philadelphia, 1994, pp 508-529
11. National Task Force on the Prevention and Treatment of Obesity: Long-term pharmacotherapy in the management of obesity. JAMA 276:1907, 1996
12. Raskin P (Ed): Medical Management of Non-Insulin-Dependent (Type II) Diabetes, 3rd ed. American Diabetes Association, Alexandria, Va, 1994
13. Saltiel AR, Olefsky JM: Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45:1661, 1996
14. Toubro S et al: The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int J Obes Relat Meta Disord 17 (Suppl 3):S73, 1993
15. Weintraub M: Long-term weight control study: Conclusions. Clin Pharmacol Ther 51:642, 1992